Andere Sprachen GRI BIOPAR

Aktien

A3D4D0

US3622AW1069

GRI

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 06.05.2024			% 5 Tage	% 1. Jan.
0,4171 ^USD	+1,74 %		-4,65 %	-93,77 %

2023	Vallon Pharmaceuticals, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2023	CI
2023	Vallon Pharmaceuticals und GRI Bio schließen Fusion ab	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity	29.04.
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar	25.04.
GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments	16.04.
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent	16.04.
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference	08.04.
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update	01.04.
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference	28.03.
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators	14.03.
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom	04.03.
GRI Bio Announces Pricing of $5.5 Million Public Offering	02.02.
Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15.12.
VALLON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	21.04.23
Vallon Pharmaceuticals, GRI Bio Complete Merger	21.04.23
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.	21.04.23
VALLON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	21.04.23
Vallon Pharmaceuticals' Stockholders Approve Merger With GRI Bio, Reverse Stock Split	21.04.23
Vallon Pharmaceuticals, Inc.(NasdaqCM:VLON) dropped from NASDAQ Composite Index	21.04.23
Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split	21.04.23
GRI Bio, Inc. completed the acquisition of Vallon Pharmaceuticals, Inc. from group of shareholders in a reverse merger transaction.	21.04.23
VALLON PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	12.04.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen GRI BIOPAR

Aktien

A3D4D0

US3622AW1069

GRI

Andere Sprachen

Filter